Gyre Therapeutics (NASDAQ:GYRE) Shares Down 12.5% – Should You Sell?

Gyre Therapeutics, Inc. (NASDAQ:GYRE)’s stock price traded down 12.5% during mid-day trading on Monday . The stock traded as low as $8.11 and last traded at $7.97. 99,280 shares were traded during mid-day trading, an increase of 17% from the average session volume of 84,647 shares. The stock had previously closed at $9.11.

Analyst Ratings Changes

Separately, Noble Financial initiated coverage on shares of Gyre Therapeutics in a research report on Tuesday, March 11th. They set an “outperform” rating for the company.

Gyre Therapeutics Price Performance

The firm has a market cap of $648.73 million, a price-to-earnings ratio of 138.60 and a beta of 1.93. The firm has a 50 day moving average price of $11.00 and a 200-day moving average price of $11.98.

Gyre Therapeutics (NASDAQ:GYRE) last announced its quarterly earnings results on Monday, March 17th. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.03). Gyre Therapeutics had a negative net margin of 84.57% and a negative return on equity of 118.43%. The firm had revenue of $27.87 million during the quarter, compared to analyst estimates of $23.50 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of GYRE. FMR LLC acquired a new position in Gyre Therapeutics in the 3rd quarter valued at about $47,000. Wells Fargo & Company MN lifted its position in shares of Gyre Therapeutics by 29.4% during the 4th quarter. Wells Fargo & Company MN now owns 4,016 shares of the company’s stock valued at $49,000 after acquiring an additional 913 shares during the period. Bank of America Corp DE grew its stake in Gyre Therapeutics by 40.4% during the fourth quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock worth $84,000 after buying an additional 1,996 shares in the last quarter. Barclays PLC increased its stake in Gyre Therapeutics by 281.8% in the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after acquiring an additional 6,855 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in shares of Gyre Therapeutics by 11.1% during the 4th quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company’s stock worth $168,000 after buying an additional 1,389 shares in the last quarter. Institutional investors own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.